Treatment of Inflammatory Bowel Disease with Biologics

335

Psoriasiform eruptions
clinical presentation, 236, 237
diagnosis, 241
genetic pathways, 240
management, 242, 243
paradoxical de novo formation/worsening,
240
pathophysiology, 240, 241
risk factors, 238–240
Pyoderma gangrenosum (PG), 52, 53

R
Radioactive immunoassay (RIA), 118, 119
Reversible posterior leukoencephalopathy
syndrome (RPLS), 318
Risankizumab, 304, 309

S
Secondary prophylaxis, 236
Serum sickness syndrome, 232
Skin allergy testing, 234
Solid organ tumors, 221
Sphingosine-1-phosphate receptor (S1P), 307
Steroid exposure preceding surgery, 136
Study of Biologic and Immunomodulator
Naïve Patients in Crohn’s Disease
(SONIC) trial, 88

T
Therapeutic drug monitoring
biologic therapies, 123, 124
clinical care, 120–122
drug levels and antibody concentrations,
120–122
immunogenicity, 293
proactive, 122, 123
vedolizumab, 293
Tissue injury, 284

Tofacitinib, 309

Tumor necrosis factor (TNF)

inflammation, 1

intestinal mucosa, 2

receptors, 2

TNF-alpha

granuloma formation, 213

immune-mediated disease processes,

213

innate and acquired immune response,

213

U

Ulcerative colitis (UC), 169

anti-TNF, 13

adalimumab (see adalimumab)

golimumab (see Golimumab)

infliximab (see Infliximab)

biologic therapies, 13, 14

in children (see Pediatric ulcerative colitis)

colonic mucosa ulceration, 13

disease severity, 13

intestinal symptoms, 134

medical management, 134

mucosal lining, colon, 113

natural history, 13

preoperative anti-TNF treatment, 137

treatment, 13

Ulcerative Colitis Long-Term Remission and

Maintenance with Adalimumab

(ULTRA 1 and 2), 15, 20–22

Ustekinumab, 304, 308

Uveitis, 51, 52

V

Vaccination strategies, pediatric IBD, 174–176

Vedolizumab, 288–293

leukocyte trafficking, gut, 304

mechanism of action, 304

Index